June 1st 2024
Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma.
May 8th 2024
The Food and Drug Administration granted a Biologics License Application for subcutaneous Opdivo for potential approval.
April 23rd 2024
When my wife was diagnosed with stage 3B melanoma, we decided to openly speak about our fears.
April 17th 2024
A type of therapy that involves “liberating” T cells from a suppressive tumor environment showed promise in the treatment of patients with uveal melanoma.
April 10th 2024
An expert explained the importance of patient choice in treatment decisions for high-risk, resectable melanoma, based on their own treatment goals.